Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses how the recent guideline update by the American Academy of Dermatology (AAD) affects dermatologists' atopic dermatitis (AD) treatment decisions.
In this interview, Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses the recent guideline update by the American Academy of Dermatology (AAD) on using phototherapy and systemic therapies to treat patients with atopic dermatitis (AD); she touches on how this update affects dermatologists' treatment decisions.
Siegfried diagnoses and treats skin-related disorders in infants and children; her specialties include AD, psoriasis, vascular birthmarks, and other eczemas. She is interested in research that investigates AD and pediatric drug development, as she participates in clinical trials for new eczema and psoriasis treatments. Siegfried is also a professor of pediatrics and dermatology in the Department of Pediatrics, Division of Dermatology, Saint Louis University School of Medicine.
Transcript
What impact does the AAD guideline update have on the decision-making process for dermatologists when considering different AD treatments?
I, personally, in my world, first of all, I only see children. At least 50% of my patients have atopic dermatitis. I always used to say it was 50% of my population, 90% of my time, because it's such a difficult condition that really requires customized treatment.
Having guidelines like this, and these are guidelines that are strictly geared toward adults, so it doesn't impact my practice at all for, I think the general dermatology population—and it was published in Journal of the American Academy of Dermatology, so it wasn't really so much geared toward allergists, family practice, or internists who also take care of this population of patients.
I would consider it being sort of a loose overview, but, again, even though this was just published, it is now outdated because there are at least 2 other topical medications that we use, and there's going to be newer biologic agents that are currently in the pipeline, and then emerging information about the JAK [Janus kinase] inhibitors. I think it's a very dynamic field, and because there's so many new things that are under development, guidelines are outdated once they're published.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More